Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Flubentylosin
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Flubentylosin (ABBV-4083) is a next-generation oral small molecule macrolide antibiotic derived from tylosin A and developed as an anti-Wolbachia agent for the treatment of filarial diseases such as onchocerciasis (river blindness) and lymphatic filariasis. It acts by inhibiting protein synthesis in Wolbachia endosymbionts essential for the survival and fertility of filarial worms. Flubentylosin demonstrates superior efficacy to doxycycline in preclinical models, with improved oral bioavailability and a shorter required dosing regimen. The drug was developed through collaboration between AbbVie and the Drugs for Neglected Diseases Initiative (DNDi), with clinical trials conducted up to Phase II before discontinuation[1][2][6][7].
- Other names
- flubentylosinABBV-4083ABBV4083ABBV 4083TylAMac
02
Targets
Bacterial 50S ribosomal subunit
Beyond the preview
Go deeper on Flubentylosin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Flubentylosin.